Eli Lilly (LLY) and Novo Nordisk (NVO) are releasing discounts for its weight-loss drugs to gain an edge and to induce health plans to cover their costs, Peter Loftus of The Wall Street Journal reports. The companies are cutting as much as half off the price tags of the over $1,000-a-month medicines. Additionally, for those who pay out of pocket, Lilly introduced vials of Zepbound that cost as little as $399 a month. To compete, Novo Nordisk is ramping up its rebating, with average Wegovy rebates up to about 51% in Q2 from 35% a year prior.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA Approval of EBGLYSS Boosts Eli Lilly’s (NYSE:LLY) Eczema Treatment Portfolio
- Eli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to Buy
- Eli Lilly announces FDA approval of EBGLYSS
- Moderna, Halliburton downgraded: Wall Street’s top analyst calls
- Eli Lilly price target raised to $1,100 from $1,050 at JPMorgan